Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero(United Biscuits (United Kingdom)), Andrew A. Lane(Dana-Farber Cancer Institute), Elizabeth A. Morgan(Brigham and Women's Hospital), Marina Konopleva(Albert Einstein College of Medicine), Anthony Letai(Dana-Farber Cancer Institute), Jon C. Aster(Brigham and Women's Hospital), Katsuhiro Togami(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Tianyu Cai(Southwest University of Science and Technology), Matthew S. Davids(Dana-Farber Cancer Institute), Leah J. Hogdal(Harvard University), Gabriel K. Griffin(Harvard University), Richard M. Stone(Dana-Farber Cancer Institute), Lucía Cabal‐Hierro(Dana-Farber Cancer Institute), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Jason Stephansky(Dana-Farber Cancer Institute)
Cited by 209
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k